Project-Based Public-Private Collaborations.
| Autor: | Hein P; Almirall SA, R&D Center, Sant Feliu de Llobregat, Barcelona, Spain., Michel MC; Department of Pharmacology, University Medical Center, Johannes Gutenberg University, Mainz, Germany. marmiche@uni-mainz.de. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Handbook of experimental pharmacology [Handb Exp Pharmacol] 2024 Aug 10. Date of Electronic Publication: 2024 Aug 10. |
| DOI: | 10.1007/164_2024_722 |
| Abstrakt: | Project-based collaborations between a single academic group and a single pharmaceutical company arguably are the most frequent form of public-private partnership in preclinical research and development of new drugs. This chapter discusses the benefits of such collaborations for both sides and potential challenges that can arise before and during the conduct of a project. This is largely based on a survey of expectations and experience by 134 academic investigators with a history of engagement in a project-based collaboration with a pharmaceutical company as well as unstructured experience directly, and learned through discussions with colleagues, from the authors. Obviously, a key benefit for both sides is achieving goals that neither could easily achieve by itself. Scientific discovery, and publications, may be a shared benefit, while for academics, funding and access to compounds, and for industry, access to assay technology and reputational factors may be important. Major hurdles can be freedom to publish and assignment of intellectual property rights. On pragmatic grounds, reaching a contract can be cumbersome, which is largely attributable to the legal expectations and needs of both parties. However, overall satisfaction with project-based collaborations appears very high for academic investigators. (© 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|